Journal ArticleOPEN ACCESS

Ixekizumab: targeting plaque psoriasis and psoriatic arthritis

  • Chaplin S
Prescriber (2019) 30(2) 37-38
DOI: 10.1002/psb.1743
N/ACitations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Ixekizumab (Taltz) is an anti‐interleukin‐17A monoclonal antibody therapy for the treatment of adults with plaque psoriasis or psoriatic arthritis. This article discusses its efficacy and place in therapy.

Cite

CITATION STYLE

APA

Chaplin, S. (2019). Ixekizumab: targeting plaque psoriasis and psoriatic arthritis. Prescriber, 30(2), 37–38. https://doi.org/10.1002/psb.1743

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free